Sensus Healthcare (NASDAQ:SRTS) Stock: Insider Joseph Sardano Acquires 30,000 Shares

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) CEO Joseph Sardano acquired 30,000 shares of Sensus Healthcare stock in a transaction that occurred on Monday, November 16th. The stock was purchased at an average cost of $2.40 per share, with a total value of $72,000.00. Following the completion of the purchase, the chief executive officer owned 1,250,293 shares in the company, valued at $3,000,703.20. The trade was a 2.46% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sensus Healthcare Stock Up 1.8%

Shares of SRTS opened at $2.30 on Thursday. Sensus Healthcare, Inc. has a 52-week low of $2.14 and a 52-week high of $5.49. The firm’s fifty day moving average is $2.93 and its two-hundred day moving average is $3.41. The stock has a market cap of $37.86 million, a PE ratio of -2.37 and a beta of 1.18.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $6.61 million. Sensus Healthcare had a negative return on equity of 24.95% and a negative net margin of 96.49%.

Wall Street Analysts Forecast Growth

SRTS has been the subject of several research reports. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, November 13th. Finally, Lake Street Capital lowered their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.83.

Check Out Our Latest Stock Report on Sensus Healthcare

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors have recently bought and sold shares of the company. Allworth Financial LP purchased a new stake in shares of Sensus Healthcare in the 3rd quarter valued at approximately $209,000. Cetera Investment Advisers acquired a new stake in shares of Sensus Healthcare during the 3rd quarter worth approximately $48,000. EP Wealth Advisors LLC acquired a new stake in shares of Sensus Healthcare during the 2nd quarter worth approximately $49,000. BlackRock Inc. purchased a new stake in shares of Sensus Healthcare during the 2nd quarter valued at approximately $252,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Sensus Healthcare during the 2nd quarter valued at approximately $303,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc. develops and markets medical devices for the treatment of non-melanoma skin cancer and other skin conditions. Its products use superficial radiation therapy, which delivers low-energy X-rays to targeted areas of the skin. The company’s product portfolio includes the SRT-100 platform and related systems designed for use in clinical settings. Sensus positions these technologies as non-invasive treatment options for conditions including basal and squamous cell skin cancers and keloids.

Featured Articles

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.